CompaniesCornerstone Pharmaceuticals

Cornerstone Pharmaceuticals

defunct
About

Defunct Company

Areas of Focus

Categories

Rebranded/RenamedBankrupt, Merged, Sold, Renamed or Otherwise Defunct
Clinical Trials (15)
View all

Total Trials

15

As Lead Sponsor

10

As Collaborator

5

Total Enrollment

828

By Phase

PHASE2: 6PHASE1: 4PHASE1/PHASE2: 2PHASE3: 2NA: 1

By Status

WITHDRAWN: 7COMPLETED: 3TERMINATED: 3ACTIVE_NOT_RECRUITING: 1UNKNOWN: 1
Clinical Trials Pipeline15 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
Today
NCT00741403
NCT00907166
NCT01537354
NCT01832857
NCT01830322
NCT03504410
Hover over trial bars to see details

Recent Trials

NCT05854966Collaborator
CPI-613 Given With Metformin in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
PHASE2Withdrawn
Started: Dec 31, 2024 · Completed: Sep 30, 2025
NCT06518538Lead Sponsor
Evaluate Efficacy of Devimistat in Combination With mFFX in 2nd Line Patients With Metastatic Pancreatic Cancer
PHASE2Withdrawn
Started: Aug 15, 2024 · Completed: Nov 30, 2026
NCT05070104Lead Sponsor
CPI-613 (Devimistat) in Combination With Modified FOLFIRINOX Plus Bevacizumab in Patients With Metastatic Colorectal Cancer
PHASE1Withdrawn
Started: Mar 30, 2023 · Completed: Nov 1, 2024
NCT05325281Collaborator
CPI-613 (Devimistat) in Combination With Chemoradiation in Patients With Pancreatic Adenocarcinoma
PHASE1Active, not recruiting
8 participants
Started: Oct 31, 2022 · Completed: Sep 30, 2025
NCT04593758Lead Sponsor
To Evaluate Maximally Tolerated Dose (MTD), Safety and Efficacy of CPI-613® (Devimistat) Plus Hydroxychloroquine in Patients With Relapsed or Refractory Clear Cell Sarcoma of Soft Tissue
PHASE1/PHASE2Completed
16 participants
Started: Sep 1, 2021 · Completed: Mar 9, 2023
View all 15 trials →
Funding History (4)
D
Mar 7, 2014
Filing
D/A
Mar 29, 2013
Filing
D
Mar 13, 2013
Filing
D
Jan 29, 2010
Filing